Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06205498Active Not Recruiting

Acalabrutinib Real World Italian obSErvational Study -ARISE

Role: collaborator

NCT06548867Recruiting

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Role: collaborator

NCT00456963Phase 4Terminated

Prevention of Diabetes and Hypertension

Role: collaborator

All 3 trials loaded